Timing correction: Solventum reports today, Wednesday, August 5, 2026, after the U.S. market close—not tomorrow. Management’s earnings webcast is scheduled for 4:30 p.m. ET.
Solventum enters 2Q with improving commercial momentum, visible cost actions, and an earnings setup that management itself flagged as unusual. The central issue is that more than $100 million of sales may have been pulled forward into 2Q ahead of the large U.S./Canada ERP cutover planned for 3Q. Those advanced distributor orders are expected to come primarily from Infection Prevention & Surgical Solutions (IP&SS) and Dental, then reverse mostly in 3Q.
That makes the headline revenue and EPS outcome less informative than usual. Investors should focus on:
The stock has already rallied sharply—roughly 27% from the May 5 earnings-date close through August 4—so the bar is likely higher than it was after 1Q.
At its May 5 1Q release, Solventum reaffirmed full-year 2026 guidance:
| Metric | FY26 outlook |
|---|---|
| Organic sales growth | +2% to +3% |
| Organic growth excluding SKU exits | +3% to +4% |
| Adjusted EPS | $6.40–$6.60, with management expecting the high end |
| Adjusted operating margin | 21.0%–21.5% |
| Free cash flow | ~$200 million |
| Tariff headwind | $100–$120 million |
The core investment question is whether 2Q results substantiate a path to the high end of EPS guidance without relying on temporary order timing.
Management previewed that it expects over $100 million of incremental 2Q sales from orders moved forward ahead of the U.S. and Canada ERP implementation in 3Q.
This is not simply a modeling detail. It will shape the market’s interpretation of the print:
Solventum’s 1Q26 results were ahead of its plan:
Segment trends provide the key starting point for 2Q:
| Segment | 1Q26 organic growth | What investors should watch in 2Q |
|---|---|---|
| MedSurg | +1.2% | Underlying recovery in wound care and IP&SS; tariff and freight pressure on segment margin |
| Dental Solutions | +3.4% | New-product momentum, normalization after prior backorder improvement, and the magnitude of ERP pull-forward |
| Health Information Systems | +4.7% | Continued growth in revenue-cycle management and autonomous coding adoption |
MedSurg: This is the largest business and remains the most important swing factor. In 1Q, Advanced Wound Care grew 2.1% organically, while IP&SS grew only 0.6% against a difficult comparison and SKU rationalization effects. Solventum’s acquisition of Acera adds reported revenue to advanced wound care, but investors should separate that contribution from organic performance.
Dental: The segment has been improving through better commercial execution, product launches, and improved supply availability. But it is also one of the businesses most exposed to the 2Q distributor-order timing benefit, so the reported growth rate may overstate the sustainable run rate.
HIS: Health Information Systems is the cleanest growth-and-margin asset in the portfolio. Its 1Q segment margin was 38.1%, and the company continues to highlight adoption of its 360 Encompass and autonomous-coding offerings. Sustained mid-single-digit growth here would support the long-term mix and margin thesis.
The margin story is constructive but still carries execution risk.
In 1Q, adjusted gross margin rose 80 basis points year over year to 56.4%, helped by savings programs, portfolio actions, sales leverage, and mix. Management cautioned, however, that the balance of 2026 should be closer to just under 56% gross margin.
The crucial 2Q questions:
Solventum continues to estimate a $100–$120 million tariff headwind for 2026. It had not booked potential tariff refunds as of 1Q because the process, timing, and ultimate recovery remain uncertain. Investors should treat any discussion of refunds as upside optionality rather than embedded earnings support unless the company actually recognizes a benefit.
The first quarter’s negative free cash flow was expected, but the company must now demonstrate the expected conversion as the year progresses.
At the end of 1Q, Solventum reported:
Management has described 1Q as the year’s low point for cash generation and expects 4Q to be the strongest quarter, aided by lower separation spending and normal tax, interest, and working-capital timing.
For 2Q, the market will be looking for a clear improvement in operating cash flow and confirmation that the company can fund:
without compromising the full-year free-cash-flow target.
Solventum is increasingly presenting itself as an active portfolio manager rather than simply a post-spin turnaround.
Key items:
An update on buyback pacing, Acera integration, and the potential for further portfolio actions could matter nearly as much as quarterly EPS.
A positive 2Q setup would include:
The key downside scenarios are:
Solventum’s 2Q report is likely to look strong on the surface because of ERP-related distributor ordering. The more consequential question is whether the company can prove that its underlying commercial engine is strengthening enough to support its long-range growth and margin targets after that temporary revenue benefit reverses in 3Q.
A clean normalization bridge, durable segment growth—especially in MedSurg and HIS—continued savings execution, and firm guidance would support the improving turnaround narrative. Conversely, ambiguity around underlying growth or the U.S. ERP cutover could limit upside after the stock’s substantial run into the event.